Lunch & Poster Viewing (Odd Numbers) — ASN Events

Lunch & Poster Viewing (Odd Numbers) — ASN Events

Lunch & Poster Viewing (Odd Numbers)

#NSWCancerConf2023

Drug targeting of colorectal cancers including cancer stem cells (#101)

Copper chelation downregulates YTHDF2 RNA-binding protein causing growth inhibition and decreased MYCN expression (#103)

Drugging the undruggable: targeting RNA-binding proteins as a therapeutic avenue against ovarian cancer (#105)

Jean Borges Bertoldo

Targeting subcellular JNK activity in pancreatic cancer (#107)

Antonia L Cadell

Characterisation of matched primary and metastatic cutaneous squamous cell carcinoma cell lines permit therapeutic testing in the immunosuppressed context (#109)

Targeting anti-androgen resistance in prostate cancer using physiologically relevant models (#111)

Michelle Devadason

Telomere remodelling in drug resistant ER+ breast cancer (#113)

Targeting autophagic initiation via both ULK1 and Beclin-1/VPS34 complexes increases chemotherapeutic potency in PDAC. (#115)

Understanding metformin’s anti-cancer effect in prostate cancer using physiological preclinical models (#117)

Loss of a growth arrest and DNA-damage inducible protein promotes resistance to a new form of cell death in leukaemia (#119)

Knocking out dipeptidyl peptidase 9 gene expression in hepatocytes increases intrahepatic levels of activated caspase-1 protein in an experimental model of hepatocellular carcinoma. (#121)

SMG1 is a negative regulator of pro-oncogenic mTOR signalling independently of Nonsense Mediated Decay (#123)

Alexander C James

Phytochemical drug combination approach to glioblastoma therapy (#125)

Kasuni Kanapaddala Gamage

Hiding in plain sight: tryptophan metabolism in hepatocellular carcinoma (#127)

Shivani Krishnamurthy

Identification of drivers of resistance in BRAF^V600E paediatric high-grade glioma and novel therapeutic targets (#129)

Rebecca Lehmann

Investigation of the presence of vasculogenic mimicry in matched primary and recurrent glioblastoma tissue (#131)

Kelsey Maddison

Therapeutic value of targeting pro-nerve growth factor and its receptor sortilin in glioblastoma (#133)

Uncovering the druggable RNA-binding proteome of childhood cancers for target-based drug discovery (#137)

Developing representative models of ovarian cancer patient response to PARP inhibitors (#139)

HPV16 and its impact on the RNA axis in head and neck cancers. (#143)

Targeting Post-Translational Protein Modifications as a Novel Therapeutic Treatment Strategy in Diffuse Intrinsic Pontine Gliomas (#145)

Arjayeeta Samadder

The Link Between Aberrations in the p53 Pathway and Outcomes from DNA-Damaging Therapies in Breast Cancer (#147)

Luiza Steffens Reinhardt

Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq. (#149)

Michael Trpceski

Effect of magnetic fields on glioblastoma cells: risk enhancement or potential adjuvant therapy? (#151)

Millijoy Villanueva

Inhibition of oxidative phosphorylation suppresses metabolically flexible glycolysis-competent cancer cell proliferation via replication stress independent of energy crisis (#153)

Investigating novel matrisomal targets in PC to reduce fibrosis and improve standard-of-care chemotherapy. (#155)

Gut microbiome alteration is linked to changes in splenic T cell populations in colorectal cancer (#157)

Miguel Q Castaneda

T-cell receptor therapies for the treatment of malignancies (#159)

Features of immunotherapy response are prevalent in melanoma brain metastases compared to high grade gliomas (#161)

Bernadette Pedersen

Targeting stromal cells to reverse immune suppression in triple negative breast cancer (#163)

Non-invasive proteomic signatures for the diagnosis and classification of keratinocytic skin lesions (#165)

Scarless biopsy proteomics to discriminate between atopic dermatitis, psoriasis, and actinic keratosis (#167)

Ultra-sensitive cancer rapid test of tumor immunotherapy biomarker (#169)

Development of a shortlist of tumour-specific methylated DNA regions with potential as a blood-based test for early ovarian cancer diagnosis (#171)

Kristina Warton

Association between perioperative factors and DAH₃₀ in oncology patients undergoing hepatobiliary resection. (#173)

David T.Y. Chen

Multiple Myeloma in the culturally and linguistically diverse Southwestern Sydney (#175)

A-M Joelle Marivel

Ovarian cancer survival by racial and ethnic group: an analysis from the Ovarian Cancer Association Consortium (#177)

Nicola S Meagher

Pharmaceutical opioid use and cancer incidence in the 45 and Up Study. (#179)

Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia (#181)

Flying a Nurse Practitioner 6-Month Pilot in Regional Outpatient Cancer Service (#183)

Implementation of Geriatric Assessments in Cancer Care: An Umbrella Review (#185)

Patient Access to Phase 1 Clinical Trials: the Scientia Experience (#187)

Charlotte Lemech

Tailoring models of care to cancer centres during implementation of the Care to Quit Trial-a smoking cessation trial for patients affected with cancer (#189)

Patient navigation to improve cancer care among ethnic minority patients: A systematic review (#191)

Acceptability of an evidence-based booklet for HPV-related oropharyngeal squamous cell carcinoma patients and their partners (#193)

Demographic and Clinical Factors Influencing Survival in Lung Cancer Patients: A Retrospective Rural Study (#195)

Alexandra Smith

Patient reported outcome measures post radical cystectomy and urinary diversion for muscle invasive bladder cancer; the symptoms that matter most to patients (#197)

UNSW Biospecimen Services, incorporating the Health Precincts Biobank: Providing high quality biospecimens and data for translational research (#199)

The effectiveness and cost-effectiveness of a digital health intervention to support breast cancer patients prepare for and recover from surgery: A randomised controlled trial protocol (#205)

Transformer-guided multi-modal feature learning to standardise thorax radiotherapy structure nomenclature (#207)

Fahim Irfan Alam

Computational modelling and simulations as tools for treatment personalisation in ovarian cancer (#209)

Marilisa Cortesi

Data-driven dietetics dashboards in the digital era: Visualising real-world, evidence-based nutrition care and outcomes for patients with head and neck cancer (#211)

Deep learning radiomics for survival prediction in non-small-cell lung cancer patients from CT images (#213)

Towards routine homologous recombination DNA repair deficiency testing for ovarian cancer patients (#215)

The Sensitivity and Specificity of Magnetic Resonance Imaging to Predict Seminal Vesicle Invasion in Prostate Cancer: A Systematic Review and Meta-Analysis (#217)

Developing a bereaved-centred model of bereavement care for Nepean Blue Mountains Local Health District. (#229)

Luna Rodriguez Grieve

Phase I/IIb dose-ranging study and development of a two-compartment model of vaporised cannabis flower bud in people with advanced cancer experiencing anorexia (#231)

Review of bereavement resources available at a NSW Local Health District. (#233)

Luna Rodriguez Grieve

PROSPER:Proliferation Signature in Prognosticating ER+ Breast Cancer (#235)

Scrutinizing the whole genome for potential genes to design an African exclusive prostate cancer germline panel (#237)

Unravelling Immunotherapy Toxicity at Single Cell Resolution (#241)

Revise, refine, reiterate: insights from beta testing an online paediatric oncology medicines database (ProCure) in preparation for implementation (#245)

Elijah Tyedmers

Quantitative proteomics analysis identified plasma extracellular vesicles and particles derived protein markers related to prostate cancer. (#247)

A qualitative exploration of fear of cancer recurrence in caregivers (#249)

Development of a brief screening tool for brain tumour caregivers' unmet needs (#251)

How do cancer survivors respond to receiving non-actionable germline genomic sequencing results? A qualitative insight. (#253)

Program factors influencing psychosocial outcomes in lung cancer screening: a systematic review (#255)

Kathleen McFadden

A longitudinal study of lung cancer stigma in newly diagnosed patients (#257)

Is conquer fear suitable for ovarian cancer survivors? (#259)

Cancer Patient Population Projections in Australia: projections of colorectal cancer (2023-2027) (#261)

Katherine Barron

Preoperative exercise and education for patients undergoing major abdominal cancer surgery. (#263)

Impact of the COVID-19 pandemic on breast cancer screening and diagnosis: A systematic review (#265)

Mammographic density measurement tools: how well do they identify population breast screeners according to breast cancer risk? (#267)

Optimising Early Detection and Management of Lung Cancer: Empowering Pharmacists to Lead Lung Health Evaluation and Prioritisation (#269)

Co-designing with General Practice to support National Bowel Cancer Screening Program participation (#271)

Stephanie SW Walker

Clinical Characteristics and Surveillance Patterns in Patients with Hepatocellular Carcinoma in Australia: A 45 and Up Study (#273)

Mutational characteristics and immune infiltrates in early colorectal polyps (#275)

A review of skin cancer primary prevention activities in primary care settings (#277)

Preventing fatty liver-related liver cancers in Australia (#279)

Joachim Worthington

Retrospective analysis of risk factors associated with cardiac hospital admissions in cancer patients treated with immune checkpoint inhibitors (#281)

Joshua Bennetts

Overexpression of mitochondrial catalase in adipose tissue improves survival and cardiac cachexia in AOM-DSS model of colitis-associated colorectal cancer. (#283)

Chronic pain in ambulatory patients attending a teaching hospital cancer centre. (#285)

Adverse Event Rates for Patients with Extensive Stage Small Cell Lung Cancer Treated at an Australian Tertiary Cancer Centre (#287)

SUPPORTIVE CARE NEEDS OF MEN DIAGNOSED WITH PROSTATE CANCER AND THEIR CLOSE ALLIES ACROSS PRIMARY TREATMENT MODALITIES (THE PCAN STUDY): A CROSS-SECTIONAL NATIONAL REGISTRY-BASED STUDY (#289)

Elizabeth Kennedy

Investigating Clinical Profiles Associated with Recovery of Chemotherapy-Induced Peripheral Neuropathy (#291)

Cross-cultural adaptation of the Breast Cancer and Lymphedema Symptom Experience Index (BCLE-SEI) in Marathi. (#293)

Vincent Singh Paramanandam

What do doctors and nurses in cancer centres tell their patients about the benefits of quitting smoking after cancer? (#295)

Exploring the barriers to optimal survivorship care for people living with cancer in NSW (#299)

The costs of survivorship care for paediatric brain cancer survivors. (#301)

Chloe Willemsen

Repurposing teniposide to target TGF-β in chemoresistant high-grade serous ovarian cancer (#303)

Michelle WY Brown

Can we measure what matters? Feasibility of clinically prioritised colorectal cancer quality indicators with a New South Wales population-based linked dataset (#305)

Candice Donnelly

Changes in numbers of circulating tumour cells as a biomarker for treatment response (#307)

Joachim Fluhrer

Combined treatment with alpelisib and gefitinib exhibits strong synergy in a metastatic gastroesophageal cancer in vitro model (#309)

Jacqueline Holliday

How are surgeons trained in endocrine surgery? A mixed method study exploring competency in endocrine surgery in Australia and New Zealand (#311)

A systematic review of dentists’ knowledge, perception, practice and confidence in managing patients with cancers. (#313)

Drug repurposing screen targeting PARP in high grade serous ovarian cancer (#315)

Bayley Matthews

Development of 3D preclinical TNBC tumour models and investigation of novel anticancer targeted therapies (#317)

Toxicity on early phase cancer clinical trials: a single institution experience in South-West Sydney (#319)

SPEAR: A Phase 2, Open-label, Single-arm Monotherapy Trial of Sulfasalazine in Pancreatic Adenocarcinoma – Trial in Progress (#321)

Omali Pitiyarachchi

Immune Checkpoint Inhibitor of Choice in Previously Treated Advanced Non-Small Cell Lung Cancer– A Systematic Review (#323)

Personalised liver stereotactic body radiation therapy using magnetic resonance imaging: The PRISM clinical trial (#325)

Sirisha Tadimalla

Exercise physiology in cancer care (#327)

Achieving Enduring Work Participation for Cancer Survivors: A Person-Centred Approach (#329)